Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Avoidance of completion pneumonectomy by sparing the right middle lobe

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient Jong Sik Lee, MD, Jae Young Hur, PhD,

MET Mutation Associated with Responsiveness to Crizotinib

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer Eiko Theodora Browning, MD, Andrew James.

Sclerosing Pneumocytoma with Lymph Node Metastasis

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

MET-Mutated NSCLC with Major Response to Crizotinib

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma Taylor M.

Electronic Updates for JTO Readers

Muhammad Umair Khawar, MD, Bhaskar Bhardwaj, MD, Himanshu Bhardwaj, MD

Difference in Clonality as a Tool for Differential Diagnosis of Primary Versus Secondary Lung Neoplasms Giovanni Leuzzi, MD, Alfredo Cesario, MD, Maria.

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First- line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor.

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Pneumonectomy-Sparing NSAID Therapy for Pulmonary Inflammatory Myofibroblastic Tumor Sofia Ghani, MD, Arpita Desai, MD, Saraswati Pokharel, MD, Todd.

Multiple Pulmonary Chondromas in a Young Female Patient: A Component of Carney Triad Gui-Bin Qiao, MD, PhD, Wei-Sheng Zeng, MD, Li-Jun Peng, MD, Wen-Zhao.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Multiple Pulmonary Chondroid Hamartoma

Histologic Transformation in NSCLC with PD-1 therapy

Vipul Pareek, MD, Mary Welch, MD, Elizabeth Ravera, RN, Richard L

CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Mark L. Kayton, MD, Mai He, MD, PhD, Maureen F. Zakowski, MD, Andre L

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy Takehito Shukuya, MD, PhD, Sandipkumar Patel,

Complete Resection of Oligorecurrence of Stage I Lung Adenocarcinoma 19 Years After Operation Dai Sonoda, MD, Masashi Mikubo, MD, Kazu Shiomi, MD, PhD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan.

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Esophagitis: A Novel Adverse Event of Crizotinib in a Patient with ALK-Positive Non– Small-Cell Lung Cancer Neeharika Srivastava, MD, Paul A. VanderLaan,

Demonstration of persistent tumor cells 4 weeks after radiofrequency ablation of a pulmonary adenocarcinoma Stéphane Renaud, Marco Schiavon, MD, Nicola.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs Patrick Micke,

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Primary Lung Cancer Presenting with Gastrointestinal Tract Involvement: Clinicopathologic and Immunohistochemical Features in a Series of 18 Consecutive.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

Phase I Study of Lenalidomide in Solid Tumors

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Successful AZD9291 Therapy Based on Circulating T790M

Journal of Thoracic Oncology

Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,

David Garfield, MD Journal of Thoracic Oncology

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the Lung Martin Frederik Dietrich, MD, PhD, Shirley Xiao Yan, MD, Joan Hoff Schiller, MD Journal of Thoracic Oncology Volume 10, Issue 5, Pages e23-e25 (May 2015) DOI: 10.1097/JTO.0000000000000448 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Radiographic evaluation of left lower lobe (LLL) (upper series) and right upper lobe (RUL) (lower series). The lesions that have taken for biopsy are marked by arrows. The timeline refers to time since initial diagnosis of LLL lesion. The upper series demonstrates continuous shrinkage after initiation of erlotinib. The patchy infiltrates at 7 months are biopsy proven to be bronchiolitis obliterans organizing pneumonia. The lower series demonstrates an RUL lesion with interval growth between baseline and 5 months, followed by significant shrinkage after initiation of crizotinib. *The 2-week time frame of drug discontinuation due to transaminitis. Journal of Thoracic Oncology 2015 10, e23-e25DOI: (10.1097/JTO.0000000000000448) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Morphologic features and immunohistochemical stains for left lower lobe (LLL) (A–C) and right upper lobe (RUL) (D–F) tumors. Hematoxylin and eosin stains for LLL (A) and RUL (D). Positive TTF-1 stains in LLL (B) and RUL (E). Positive napsin A staining in LLL (C) and negative staining in RUL (F). Journal of Thoracic Oncology 2015 10, e23-e25DOI: (10.1097/JTO.0000000000000448) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions